Introduction
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will have a persistent salivary gland infection with multiple, distinct virus isolates (Booth et al., 1993) . Likewise, infection with human cytomegalovirus (HCMV) is highly prevalent and is a significant cause of morbidity and mortality in immunosuppressed or immunoincompetent individuals, such as transplant recipients, AIDS patients and the fetus (reviewed by Ho, 1991) ; co-infection with several distinct strains can occur (Drew et al., 1984) . Because of the strict species specificity of the cytomegaloviruses, MCMV infection of mice has been used as a model for HCMV (Hudson, 1979; Staczek, I990) . Most studies of MCMV have utilized the laboratory strains Smith and K181. We have derived a panel of novel isolates of MCMV from wild mice which, on the basis of restriction fragment length polymorphism analysis, are genetically distinct from the Smith and K18I strains (Booth et al., 1993) . This raises the important consideration of the extent of variation in immunologically important proteins. Recently, we have established that significant genetic variation exists in several regions of the MCMV glycoprotein B molecule, a viral protein that elicits an antiviral antibody response (Xu et al., 1996) .
While antibodies induced during MCMV infection can have a useful role in host-protection against viral challenge, their role in resolving established infections is limited (Jonjic et al., 1994) . In contrast, T cells have been found to be critical for the elimination of MCMV from the BALB/c strain of mice (reviewed by Koszinowski et al., 1990 Koszinowski et al., , 1992 , a response that is predominantly mediated by CD8 +, MCMV-specific, class I MHC-restricted T cells (Reddehase et al., 1985) . Studies on the specificity of T cells from BALB/c mice infected with the Smith strain of MCMV have revealed that almost 50% of CD8 + T cells are specific for phosphoprotein pp89, the product of the ieI gene (Reddehase & Koszinowski, 1984; Koszinowski et al., 1987) . Epitope mapping studies, using vaccinia virus recombinants expressing pp89 and synthetic peptides, have shown that this protein contains a single, immunodominant, H-2L drestricted CD8 + T cell epitope with the sequence YPHFMPTNL (Del Valet aI., 1988; Reddehase et al., 1989) . Immunization of mice with vaccinia virus constructs expressing either the entire pp89 protein, or the nonapeptide sequence, has been shown to protect mice against lethal infection with MCMV Del Valet al., 1991 b) . Furthermore, vaccination strategies utilizing the YPHFMPTNL nonapeptide in adjuvants have been shown to elicit CTL responses that reduce MCMV replication in the spleen (Scalzo et al., 1995 a) .
Studies of sequences representing CTL epitopes of a number of RNA viruses, such as human immunodeficiency virus (HIV; Pircher et al., 1990; Phillips et al., 1991) and lymphocytic choriomeningitis virus (LCMV; Lewicki et al., 1995 a, b; Moskophidis & Zinkernagel, 1995) , and of a number of DNA viruses, such as Epstein-Barr virus (EBV; Apolloni et al., 1992) and hepatitis B virus (HBV; Bertoletti et al., 1994) , have demonstrated that these viruses can produce variant sequences at CTL epitopes. In the case of LCMV, variants that escape CTL recognition have been generated in vitro by incubation of virus-infected ceils with CTL clones (Lewicki et al., 1995 a) . As MCMV is a natural infectious agent of mice the evaluation of genetic heterogeneity in genes, such as iel, provides scope for analysis of the consequences of such variation on evasion from immune surveillance. The aim of this study was therefore to determine the extent of variability of the MCMV iel gene in the vicinity of the immunodominant epitope YPHFMPTNL, and to assess the consequences of this variation on CTL recognition and protection.
Methods
• Mice. Specific pathogen-free, female BALB/c and outbred Swiss/Arc mice were obtained from the Animal Resources Centre (Murdoch, Western Australia) and housed under minimal disease conditions. Mice were immunized at 6-8 weeks of age.
• Cell culture. Primary mouse embryo fibroblast (MEF) cultures were prepared by trypsin dispersion of 14-I5-day-old embryos from either BALB/c or outbred Swiss/Arc mice as described previously (Chalmer et al., 1977) . MEF were cultured in MEM (Gibco-BRL) supplemented with 10 % fetal calf serum (FCS), 40 rtg/ml gentamicin and 100 U/ml penicillin. P815 (H-2a), EL4 (H-2 b) and CV-1 cells were obtained from ATCC and were grown in RPMI 1640 (Gibco-BRL) supplemented with 2 mM-Lgiutamine, 50 mM-2-mercaptoethanol and 10% FCS.
• Viruses, The origin, isolation and plaque purification of the field isolates of MCMV have been described elsewhere (Booth et al., I993) . The MCMV laboratory strains used were K181 (obtained from D. Lang, Duke University, Durham, N.C., USA), Vancouver (kindly provided by J. Hudson, University of British Columbia, Vancouver, Canada) , and Smith (kindly provided by E. Mocarski, Stanford University, Calif., USA) . Salivary gland passaged virus (SGV) stocks of all strains were prepared in 3-week-old female BALB/c mice as described elsewhere (Allan & Sheilam, 1984) , while tissue culture virus (TCV) stocks were prepared by propagation in MEF. All viral stocks were stored in the gas phase of liquid nitrogen and quantified by plaque assay on MEF. Viral DNA was prepared essentially as outlined by Mocarski et aI. (1980) , except that the lysis buffer used contained 0'5 % (w/v) sodium deoxycholate in addition to 1% (v/v) NP40.
A recombinant vaccinia virus expressing the ieI gene of the Smith strain of MCMV (MCMV-iel-vac: kindly supplied by U. Koszinowski, University of Heidelberg, Heidelberg, Germany) (Volkmer et al., 1987) , was propagated in CV-1 cells.
• PCR amplification of the MCMV tel gene. A 3104 bp fragment of the MCMV iel gene was amplified from purified viral DNA by PCR using the iel-specific oligonucleotide primers IElfor (5' TGCAGGATCCTGCCCAAGAA 3') and IElrev (5' CTGGGCTTG-TGAATTCACTT 3"). The two primers correspond to nucleotides 46--65 and 3131-3150, respectively, of the published iel sequence . Single base-pair mismatches (underlined) were included in the primer sequences to introduce unique restriction enzyme sites in the amplified product to facilitate cloning. PCR reaction mixtures contained 100 ng of viral DNA, 60 ng of each amplification primer, 2 mM-MgCl~, 0"2 mM-dNTPs and 2 U of Taq DNA poIymerase in I x standard PCR buffer. The PCR amplification parameters used were 5 min at 95 °C, 2 min at 54 °C and 9 min at 70 °C for 1 cycle, followed by I min at 95 °C, I rain at 54 °C and 6 min at 70 °C for 29 cycles.
• Nucleotide sequencing. The ieI PCR products were sequenced directly by the dideoxynudeotide chain termination method using a double-stranded DNA cycle sequencing kit (Gibco-BRL) according to the manufacturer's instructions. The sequencing primer employed, IElseq (5' GAACTATCAATCAGCCA 3'), corresponds to nucieotides 1696-1712 of the published iel sequence (Keil et al., I987) . Sequences were determined at least twice for each strain. Sequence alignments, and the determination of putative protein sequences were performed using MacVector sequence analysis software (IBI).
• Priming and in vitro restimulation of CTL CTL specific for pp89 were generated by infecting BALB/c mice with 2 x I07 p.f.u, of MCMV-iel-vac by the intraperitoneal (i.p.) route. MCMV-specific T cells were primed in BALB/c mice infected with I x 10 a p.f.u, of SGV stocks of MCMV by the i.p. route. Single cell suspensions of splenocytes were prepared 3-4 weeks later. Following lysis of erythrocytes with Trisbuffered ammonium chloride (0"14M-NH4C1, 17mM-Tris, pH 7'2), lymphocytes were resuspended in RPMI I640 supplemented as described above. Stimulator ceils were BALB/c MEF monolayers in 24-well trays that were infected with 3 x I04 p.f.u, per well of TCV stocks of MCMV by centrifugal enhancement (Hodgkin eta/., I988) . After 24 h the monolayers were exposed to UV light for 5 min and then 5 x 10 ~ lymphocytes were added to each well. Cultures were then incubated for 5 days at 37 °C, harvested and tested in a CTL assay.
• CTL assay. The assay was performed essentially as described by Ho (1980) . Target cells expressing MCMV immediate-early antigens were prepared as follows. BALB/c MEF monolayers were infected by centrifugal enhancement with I x I06 p.f.u./ml of TCV stocks of MCMV in the presence of cycloheximide (50 gg/ml). After 3 h the medium containing the cycloheximide was removed and replaced with flesh medium containing actinomycin D (5 gg/ml), and the cells were incubated for a further 2 h.
Target cells expressing MCMV early or late proteins were prepared by infecting MEF in the presence (early targets), or absence (late targets) of phosphonoacetic acid (PAA; 250 gg/ml) for 24 h. Target cells were labelled with 125 l~Ci Naz51CrO4 (Amersham) and dispensed at I x I0 4 target cells per well of 96-well microtitre plates. P815 and EL4 target cells were pre-incubated with nonapeptides (kindly provided by A. Suhrbier, Queensland Institute of Medical Research, Brisbane, Queensland, Australia), or medium alone for I h at 37 °C. Effector cells were added in triplicate to target preparations to give a range of effector:target (E:T) ratios and 51Cr release was determined 4-6 h later. Results are expressed as % specific lysis calculated as: (% release induced by effector cells-% spontaneous release)/(% total release-% spontaneous release).
• Immunization with the tel synthetic peptide and MCMV challenge. Mice (five per group) were immunized with the peptide YPHFMPTNL in the presence of the adjuvant Montanide ISA 720 (M720) (Seppic, France) and tetanus toxoid essentially as described previously (Scalzo et al., 1995 a) . The peptide, adjuvant and Tet. Tox. preparations were kindly provided by A. Suhrbier. Two weeks after peptide immunization mice were challenged by i.p. infection with a sublethal dose of 8 x IO a p.f.u, of SGV stocks of different MCMV isolates or of the K181 strain. As positive controls, groups of five mice were immunized by infection with 5 x 10 a p.f.u, of homologous strains of MCMV 4 weeks before virus challenge. Data were compared statistically using Student's Mest.
Results

PCR amplification and sequencing of the MCMV tel gene
To determine whether sequence variation occurs in MCMV field isolates at a previously identified CTL epitope, the iel gene was amplified by PCR, and a region encompassing the epitope sequenced. The ieI gene was amplified from the two laboratory strains, K181 and Vancouver, and 27 field isolates of MCMV. In all cases the amplification reaction gave rise to a product of the expected size, 3" 1 kb.
The nucleotide sequence of a 138 bp region, corresponding to nucleotides 1787-1924 of the published sequence of the Smith strain of MCMV (Keilet a]., 1987), was determined for all 29 strains. The predicted protein sequences for each strain (corresponding to amino acids 147-192) were determined and aligned to the published Smith strain sequence (Fig. 1) . The K181 and Vancouver laboratory strains, and eight of the field isolates had sequences identical to that of the Smith strain. In the remaining 19 isolates, sequence variation was observed at I4 nucleotide positions. The extent of variation ranged from five (4 %) to seven (5 %) nucleotides in any one strain over the region sequenced. Of the I4 nucleotide substitutions only two were silent; that is, they did not lead to a change in the amino acid sequence. These were a C ~ T substitution at nucleotide position 1822 which was observed in the G4 and G5 strains, and a T ~ C substitution at nucleotide position 1873 which was observed in all strains that exhibited variation from the published sequence, except for K4 and N1. The remaining 12 nucleotide substitutions all led to amino acid changes ( Fig. 1 ). Of these 12 amino acid substitutions, five occurred within the nonapeptide 168-YPHFMPTNL-176 which constitutes the T cell epitope identified by Reddehase et aI. (1989) . All 19 variant isolates had an A -+ C substitution at nucleotide position 1868, which results in the substitution of a proline for threonine at amino acid residue 174. Seventeen of the variant isolates also have an A ~ G substitution at nucleotide position 1872 resulting in the substitution of a serine for asparagine at amino acid residue 175. Additionally, nine of the isolates have a G ~ A substitution at position 1864 leading to the substitution of an isoleucine for methionine at amino acid residue 172. Isolate N1 has, in addition to the A ~ C substitution at position 1868, a C-~ T substitution at position 1854 and a C ~ G substitution at position 1856 resulting in the substitution of a leucine for proline and an aspartate for histidine at amino acid residues 169 and 170, respectively.
On the basis of variation within the T cell epitope, the 29 strains could be divided into a group of ten strains with sequences identical to the Smith strain, containing the two laboratory strains K181 and Vancouver, and the field isolates WS, W7, WS, WE6, W8211, W9077, G2 and K17A (nonapeptide sequence YPHFMPTNL), and four variant groups. The first variant group consists of the single isolate K4, which has just the proline substitution at position 174 (nonapeptide sequence YPHFMPPNL). The second variant group comprises eight field isolates, W6, GIA, G3A, G3B, G3D, G3E, G4 and GS, which have the proline and serine substitutions at residues 174 and 175, respectively (nonapeptide sequence YPHFMPPSL). The third variant group contains nine isolates, K6, K7, K29, KI7B, K17C, K17D, K17E, K17F and K17G, all of which have the isoleucine, proline and serine substitutions at amino acid residues 172, 174 and 175, respectively (nonapeptide sequence YPHFIPPSL). The final variant group contains the single isolate N1, which in addition to the proline substitution at residue 174, has the leucine and aspartate substitutions at amino acid residues 169 and 170, respectively (nonapeptide sequence YLDFMPPNL).
Effect of sequence variation on CTL recognition
To determine the effect of sequence variation on CTL recognition, the ability of YPHFMPTNL sequence-specific, CD8 + cells to lyse cells infected with representative viruses from each variant group was measured. CTL were induced by immunization of mice with MCMV-iel-vac followed by in vitro On 
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restimulation with UV-irradiated, MCMV (strain K181)infected BALB/c MEF (Fig. 2) . High levels of specific killing by these restimulated cells were observed for target cells infected with viruses with non-variant sequences KI81 and G2 (Fig. 2) , K17A, W5 and WE6 (data not shown), and for P815 cells pulsed with YPHFMPTNL peptide representing the pp89 epitope of the prototypic Smith strain (Fig. 2) . Greatly reduced levels of specific killing were observed for targets infected with representative viruses from variant groups I, 2 and 3, K4, G4, K6 (Fig. 2) , K7 and K29 (data not shown). No killing was observed with either targets infected with the variant group 4 isolate, N1, or uninfected targets (Fig. 2) . In addition, minimal lysis was observed with YAC-1 targets indicating little contribution of natural killer cell activity in the assay (data not shown).
Recognition of the nonapeptide YPHFMPTNL by polyclonal, virus-specific CD8 + T cells
To assess whether CTL induced by infection with isolates with variant pp89 sequences could recognize the YPHFMPTNL sequence, polyclonal populations of MCMVspecific CTL were raised by infecting BALB/c mice with K181, or the G4, K6 or N1 isolates. BALB/c MEF infected with the homologous viruses and then UV-irradiated were used to restimulate the CTL in vitro. These were tested for their ability to lyse P815 cells incubated with the prototype peptide YPHFMPTNL. CTL raised against KI81, G4 and K6 (Fig.  3 a-c, respectively) lysed P815 cells pulsed with peptide. In contrast, CTL from mice infected with N1 did not lyse these peptide-coated target cells (Fig. 3 d) . The lack of killing by the N1 primed cells was not due to a total lack of CTL activation by this virus, since these CTL lysed MEF infected with the N1 isolate ( Fig. 3f ) at levels comparable to those of K181 primed CTL against KISI-infected MEF (Fig. 3 e) . Both N1-and K181induced CTL showed similar patterns of killing of infected target cells incubated with the different metabolic inhibitors to express predominantly immediate-early, early or late viral antigens. The NI-induced CTL also exhibited similar levels of killing of targets infected with the heterologous strain K181 (data not shown) indicating cross-reactive CTL activity induced against viraI target antigens. 
Ability of pp89 variant isolates to elicit CTL responses that recognize homologous pp89 peptide sequences
To determine if the pp89 sequences of the variant isolates could elicit responses reactive with the homologous variant nonapeptides, BALB/c mice were infected with the G4 (variant group 2), K6 (group 3) or N1 (group 4) isolates, or with K18I as a positive control, and these were tested for lysis of target cells incubated with peptides homologous to the pp89 100 80 0 10-9 10-8 10-7 10-6 10-9 10-4
Peptide concentration (M) Fig. 4 . CTL induced by variant MCMV isolates against homologous pp89 variant peptides. Splenocytes from BALB/c mice infected with the pp89 variant isolates G4 (I), K6 (0) or N1 (O), orthe laboratory strain K181 (El) were restimulated in vitro with the homologous strain and then tested for lyric activity at 60:1 to 1 5:1 against MEF infected with the homologous virus isolate or with P815 cells incubated with a range of concentrations of the homologous variant peptides YPHFMPPSL, YPHFIPPSL, YLDFMPPNL or YPHFMPTNL, respectively. Lysis of peptidetreated P815 cells at the 30:1 E:T ratio are shown and are representative.
sequences of the priming isolate. Splenocytes from infected mice were re-stimulated in vitro by culture with the homologous priming strain. After 5 days the cells were tested for reactivity against H-2 matched P815 (H-2 ~) or H-2-mismatched EL4 (H-2 b) targets incubated with 10-fold dilutions of homologous peptides. Fig. 4 clearly shows that the group 2 and 3 isolates, G4 and K6, elicited CTL with reactivity against the homologous variant peptides YPHFMPPSL and YPHFIPPSL, respectively. The N1 isolate did not induce a response to the YLDFMP_PNL homologous variant peptide, although strong killing of Nl-infected MEF was observed (data not shown sequences of the group 2 and 3 isolates can elicit CTL responses after homologous priming.
Assessment of cross-protection against challenge with MCMV field isolates exhibiting sequence variation in the iel nonapeptide
To investigate whether CTL responses primed with the YPHFMPTNL sequence can protect against viruses exhibiting sequence variation in this nonapeptide, mice were immunized with the YPHFMPTNL peptide and challenged with KI8I or with field isolates exhibiting ieI sequence variation. For the immunizations, mice were injected with the peptide (YPHFMPTNL) and tetanus toxoid emulsified in Montanide ISA 720 using the previously established protocol (Scalzo et al., 1995a) and then challenged with K181, G4 or N1 viruses. Control groups were pre-immunized by infection with the homologous strain of virus or by immunization with tetanus toxoid emulsified in adjuvant without peptide. For the group 2 and 4 viruses, G4 and N1, respectively, pre-immunization with the peptide YPHFMPTNL did not reduce virus replication in the spleens of challenged mice (G4: peptide immunized, 3"0 ___ 0"3 log10 p.f.u, per spleen, versus adjuvant alone controls, 3"1+0"1 log10 p.f.u, per spleen; NI: peptide immunized, 3"6-t-0"2 log10 p.f.u, per spleen, versus adjuvant alone controls, 3"2+0"2 log10 p.f.u, per spleen). In contrast, as observed previously (Scalzo et al., 1995a) , YPHFMPTNL peptide immunization significantly protected against K181 replication (peptide immunized, 4"2 q-0"2 log10 p.f.u, per spleen, versus adjuvant alone controls, 5"0__.0"1 log10 p.f.u, per spleen, P = 0"022). Prior immunization with virus led to complete protection against all three viruses (titres were all < 20 p.f.u. per spleen). While the overall levels of virus replication with G4 and N1 were lower than those of K181, reflecting the reduced virulence of these isolates, no peptide-induced protection was observed.
Discussion
These studies show that immunization with a peptide derived from the sequence of a laboratory strain of MCMV induces only weak T cell recognition of virus isolates exhibiting nucleotide sequence changes within the CTL epitope. As a consequence mice immune to the immunodominant epitope are not necessarily protected from infection by field isolates of MCMV. The observations are explained, for the isolates that showed reduced T cell recognition relative to the laboratory strain of MCMV, by the occurrence of sequence variation within the nonapeptide T cell epitope 168-YPHFMPTNL-176 which could be classified into four groups: (1) YPHFMPPNL;
(2) YPHFMPPSL; (3) YPHFIPPSL; and (4) YLDFMPPNL.
Target cells infected with field isolates encoding variant pp89 sequences were sensitive to lysis by CTL primed to the homologous strain of virus. Thus, it appears likely that the polyclonal population of MCMV-ieI-vac-primed, MCMV K18I-restimulated CTL respond weakly to the field isolates due to suboptimal recognition of the pp89-derived variant peptides, although the presentation of the variant peptides by H-2L d has not been formally shown. The function of each residue within amino acids 168-176 has been characterized previously (Corr et al., 1992; . Isolate N1 (group 4) contains a non-conservative substitution at residue P-169, one of two residues that anchor the peptide to the H-2L ~ MHC class I glycoprotein. Thus, the lack of recognition by pp89 (YPHFMPTNL)-specific CTL is likely to be due to an inability of the YLDFMPPNL peptide to bind to H-2L a.
Apart from the N1 isolate, all of the other variants showed one to three substitutions solely in the amino acid residues spanning 172-MPTN-175 of the region 168-176. Previous studies by Reddehase & Koszinowski (199I) , using single alanine substitutions in YPHFMPTNL, revealed that the amino acids in the region 172-MPTN-175 did not have a role in binding to H-2L a or to the T cell receptor (TCR), and were likely to represent contiguous spacer positions. Substitutions of the amino acids I72-MPTN-175 by tetra-alanine or tetraproline were found to abrogate recognition by a pp89-specific CTL clone, indicating that the spacer residues have a critical cooperative effect on peptide antigenicity . In the present study, target cells infected with the K4 (group I) isolate, which has the single proline for threonine substitution at position 174 in the nonapeptide, were only weakly recognized by pp89 (Smith)-specific CTL. It is possible that this non-conservative substitution may be tolerated less well in terms of CTL recognition than a substitution of threonine for alanine at this position. Likewise, poor pp89-specific CTL recognition of all group 2 and 3 isolates may be accounted for by the threonine for proline substitution, with further contributions by the additional substitutions at amino acid residues 172 and 175. This latter hypothesis is supported by the observation that substitution in 172-MPTN-I75 by tetra-proline abrogated recognition by a pp89-specific CTL clone Regions flanking CTL epitopes have also been found to influence the antigenicity of sequences including those of pp89 (Del Valet al., 1991a) . We have identified seven changes in the amino acid sequence surrounding the CTL epitope in the region between residues 147 and 192 and it is not known to what extent these influenced the processing or presentation of the peptide. However, target cells infected with MCMV variant group 2 (YPHFMPPSL) and group 3 (YPHF_IPPSL) were poorly recognized by pp89 (YPHFMPTNL)-specific CTL. Both of these groups expressed a characteristic set of residue changes in the flanking sequences involving combinations of differences defined by the presence of residue substitutions at 152 (R--*K), 164 (M~I) and 192 (I--+T) (see Fig. 1 ). Therefore, these do not appear likely to have influenced CTL recognition of the MCMV isolates. An exception is that the '.62C change of methionine for isoleucine at position 147 was found in all variant viruses and therefore also correlates with reductions in T cell recognition. The potential role of this amino acid residue cannot be resolved with the current panel of isolates, since none of these showed sequence variation at residue 147 in the absence of variation at the CTL epitope. However, in a recent study using a polyepitope consisting of a string of nine CTL epitopes, including the iel-encoded sequence YPHFMPTNL, joined contiguously, there was no evidence of any influence of adjoining amino acid residues on the steps of antigen processing and presentation (Thomson et al., 1995) .
In isolate G4 (YPHFMPPSL), variations in the amino acid sequence of the CTL epitope have occurred in the region previously assigned a spacer function in the peptide , with conservation of the critical residues for MHC binding and TCR interaction. The finding that cells infected with isolate G4 are poorly killed by pp89 (Smith strain)-specific CTL, whereas G4-primed CTL kill heterologous YPHFMPTNL or homologous YPHFMPPSL peptide-pulsed targets at a high level, raises the possibility that the variant sequence of G4 may function as an inhibitor or competitor of binding of standard peptide to the MHC, or act as an antagonist or agonist of the TCR interaction with peptide-MHC. Indeed, have shown that a peptide analogue of YPHFMPTNL incorporating a tetra-proline substitution in the region I72-MPTN-175 was able to function as a potent competitor of the prototype peptide YPHFMPTNL. The phenomena of inhibition and antagonism may be exploited by pathogens to evade or misdirect the immune system (reviewed by Jameson & Bevan, 1995) . Given the high proportion of MCMV isolates that exhibit variation in the iel CTL epitope it is of considerable importance to determine if this variation leads to escape from CTL immune surveillance. The finding that isolate K17A, which has the prototype sequence YPHFMPTNL was present in the same mouse as group 3 isolates with the potentially inhibitory YPHFI_PPSL sequence (i.e. KI7B ~ KI7F) indicates the opportunity may exist for this to occur in vivo. In recent studies, it has been suggested that HBV and HIV-I evade the CTL response through antagonism of TCR-peptide-MHC interaction by naturally occurring variants of nucleoprotein of HBV (Bertoletti et al., 1994) and Gag protein of HIV-I (Klenerman et al., 1994) . The in vivo significance of antagonism or agonism by peptides that lead to activation of some, but not all, functions of CTL cannot be readily assessed using either HIV-I or HBV, but this may be possible through study of MCMV in its natural host, the mouse. This model may also allow investigation into whether escape from CTL recognition contributes to viral persistence.
Another issue to be addressed concerns the development of sequence variation in persistent DNA virus infections, such as MCMV and EBV, that generally have low pathogenicity. It is possible that sequence variants arise from immune pressure, random mutation or recombination between strains of virus. Recent studies have suggested that the presence of the HLA-All class I molecule in humans has influenced sequence variation in a CTL epitope of EBV (de Campos-Lima et al., 1994) . In the case of MCMV, the operation of immune pressure-driven variation in pp89 would dictate that each wild mouse contained H-2L a, which seems an unlikely scenario. The concept of immune pressure driving pp89 variation might be more credible if the peptide bound to the product of more than one H-2 allele, and it has been reported that YPHFMPTNL peptide binds to H-2K b in addition to H-2L a (Dutz et al., 1992; Kageyama et al., 1995) . Random mutation may be present, if this region of pp89 containing the nonapeptide sequence is not involved in an essential function, and therefore is not highly conserved. It appears likely, however, that new strains of MCMV could result from recombination since simultaneous infection of mice by multiple strains of virus was found (Booth et al., 1993) . This explanation is relevant to human infection since several strains of HCMV can be recovered simultaneously from patients with AIDS (Drew eta]., 1984) .
The finding that target cells infected with the N1 strain of MCMV which were not recognized by pp89 (Smith strain)specific CTL were lysed by Nl-primed CTL raises the question of which epitope and restricting elements were used in this situation. It is possible that a sub-dominant epitope in the N1 strain that is also present in the Smith strain of MCMV was recognized, or that sequence changes in the NI strain resulted in the formation of a new epitope within pp89 or another site. Recent studies by Lewicki et al. (1995 b) , using CTL escape variants of LCMV, have shown that the host can mount hostprotective responses to sub-dominant 'weak' epitopes in the absence of 'stronger' dominant epitopes. Subsequent to MCMV Smith strain infection of BALB/c mice, pp89 accounts for approximately 50% of the MCMV-specific CD8 + T cell repertoire induced (Reddehase & Koszinowski, 1984; Koszinowski et al., 1987) , but as yet the other sub-dominant epitopes have not been defined.
Immunodominant sequences are generally selected for vaccine development. However, if these sites are subject to high levels of sequence variation, as found for example in HIV-1 (Pircher et al., 1990; Phillips et al., 1991) , then analysis of the sub-dominant epitopes may be more desirable. Since persistence of long-term T cell memory may depend upon repeated restimulation with antigen then immunity to the immunogen pp89 may wane if the reinfecting MCMV strains differ in sequence from the vaccine. Thus, viral products such as glycoprotein M which show stability of sequence between field isolates of MCMV (Scalzo et aI., 1995 b ) may be more useful vaccine candidates, even if they do not usually dominate the CTL response during natural infection.
